000168945 001__ 168945
000168945 005__ 20240229133631.0
000168945 0247_ $$2doi$$a10.1007/s00259-021-05374-4
000168945 0247_ $$2pmid$$apmid:34018010
000168945 0247_ $$2ISSN$$a0340-6997
000168945 0247_ $$2ISSN$$a1432-105X
000168945 0247_ $$2ISSN$$a1619-7070
000168945 0247_ $$2ISSN$$a1619-7089
000168945 037__ $$aDKFZ-2021-01147
000168945 041__ $$aEnglish
000168945 082__ $$a610
000168945 1001_ $$aKoerber, Stefan A$$b0
000168945 245__ $$aNovel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT.
000168945 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2021
000168945 3367_ $$2DRIVER$$aarticle
000168945 3367_ $$2DataCite$$aOutput Types/Journal article
000168945 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1634305815_1826
000168945 3367_ $$2BibTeX$$aARTICLE
000168945 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000168945 3367_ $$00$$2EndNote$$aJournal Article
000168945 500__ $$a#LA:E060#/2021 Nov;48(12):3918-3924
000168945 520__ $$aA high expression of fibroblast activation protein (FAP) was observed in multiple sarcomas, indicating an enormous potential for PET/CT using 68Ga-radiolabeled inhibitors of FAP (FAPI). Therefore, this retrospective study aimed to evaluate the role of the novel hybrid imaging probe for sarcomas as a first clinical evaluation.A cohort of 15 patients underwent 68Ga-FAPI-PET/CT for staging or restaging. The acquisition of PET scans was performed 60 min after administration of 127 to 308 MBq of the tracer. The uptake of 68Ga-FAPI in malignant tissue as well as in healthy organs was quantified by standardized uptake values SUVmean and SUVmax.Excellent tumor-to-background ratios (> 7) could be achieved due to low background activity and high SUVmax in primary tumors (median 7.16), local relapses (median 11.47), and metastases (median 6.29). The highest uptake was found for liposarcomas and high-grade disease (range 18.86-33.61). A high SUVmax (> 10) was observed for clinically more aggressive disease.These preliminary findings suggest a high potential for the clinical use of 68Ga-FAPI-PET/CT for patients diagnosed with sarcoma.
000168945 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000168945 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000168945 650_7 $$2Other$$aFAPI
000168945 650_7 $$2Other$$aFibroblast activation protein
000168945 650_7 $$2Other$$aPET
000168945 650_7 $$2Other$$aSUV
000168945 650_7 $$2Other$$aSarcoma
000168945 7001_ $$aFinck, R.$$b1
000168945 7001_ $$aDendl, K.$$b2
000168945 7001_ $$aUhl, M.$$b3
000168945 7001_ $$aLindner, T.$$b4
000168945 7001_ $$aKratochwil, C.$$b5
000168945 7001_ $$aRöhrich, M.$$b6
000168945 7001_ $$aRathke, H.$$b7
000168945 7001_ $$aUngerechts, G.$$b8
000168945 7001_ $$aAdeberg, S.$$b9
000168945 7001_ $$aHerfarth, K.$$b10
000168945 7001_ $$aJaeger, D.$$b11
000168945 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, J.$$b12$$udkfz
000168945 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, U.$$b13$$udkfz
000168945 7001_ $$0P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aGiesel, Frederik$$b14$$eLast author$$udkfz
000168945 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-021-05374-4$$n12$$p3918-3924$$tEuropean journal of nuclear medicine and molecular imaging$$v48$$x1619-7089$$y2021
000168945 909CO $$ooai:inrepo02.dkfz.de:168945$$pVDB
000168945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000168945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000168945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000168945 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000168945 9130_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000168945 9141_ $$y2021
000168945 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-02-02$$wger
000168945 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-02
000168945 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-02
000168945 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-02
000168945 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-02-02
000168945 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-02
000168945 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-02-02
000168945 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-02
000168945 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-02
000168945 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-02-02
000168945 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-02-02
000168945 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2019$$d2021-02-02
000168945 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2019$$d2021-02-02
000168945 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x0
000168945 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x1
000168945 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x2
000168945 980__ $$ajournal
000168945 980__ $$aVDB
000168945 980__ $$aI:(DE-He78)HD01-20160331
000168945 980__ $$aI:(DE-He78)E050-20160331
000168945 980__ $$aI:(DE-He78)E060-20160331
000168945 980__ $$aUNRESTRICTED